Rapid Insights Ep.5: The Weight Is Over: Obesity Drugs Have Arrived

In this rapid insight episode, we look at the rise of weight-loss drugs. Don’t sleep on this theme, there may be some dramatic investment implications. Targeting obesity, these drugs are not just a healthcare game changer but may also have a profound economic impact on the estimated 3% of global GDP that obesity costs. Leading this transformation are companies like Novo Nordisk and Eli Lilly, which we look at in more detail in the podcast. Beyond healthcare, the influence of these drugs could extend to industries like fast food, gyms, luxury goods and health insurance. This pivotal development in healthcare reflects the evolving investment landscape, shaped by breakthrough medical advancements and their widespread implications.

Read the Blog Post here Watch the full episode ⁠⁠here⁠⁠ To listen in podcast form click ⁠⁠⁠⁠here⁠⁠⁠⁠

Get an obligation-free ⁠⁠⁠⁠portfolio recommendation⁠⁠⁠⁠ to see how we would invest for you

Learn more about the ⁠⁠⁠⁠hosts⁠⁠⁠⁠

Find us on social media:

⁠⁠⁠⁠Twitter⁠⁠⁠⁠

⁠⁠⁠⁠Instagram⁠⁠⁠⁠

⁠⁠⁠⁠Facebook⁠⁠⁠⁠

⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠

Want to know more?  ⁠⁠⁠⁠Click here to Subscribe⁠⁠⁠⁠

Nucleus Wealth is an Australian Investment & Superannuation manager that can help you reach your financial goals through transparent, low-cost, ethically tailored portfolios. To find out more head to ⁠⁠⁠⁠Nucleus Wealth Website⁠⁠⁠⁠.

The information on this podcast contains general information and does not take into account your personal objectives, financial situation or needs. Past performance is not an indication of future performance. Damien Klassen is an authorised representative of Nucleus Wealth Management. Nucleus Wealth is a business name of Nucleus Wealth Management Pty Ltd (ABN 54 614 386 266 ) and is a Corporate Authorised Representative of Nucleus Advice Pty Ltd - AFSL 515796

Responsible Investing DisclaimerNucleus Wealth offers all investors the option to tailor their investment portfolios according to the investor’s own brand of personal ethics. While Nucleus Wealth maintains ethical standards of integrity, honesty and reliability, it does not seek to impose these on its investors. Rather, Nucleus Wealth offers investors a system of investment that incorporates three core strategies: (i) customisable; (ii) transparent; and (iii) safe. Within this, investors are given the ability to customise their investments insofar as it aligns with their ethical preferences, rather than that of the fund manager, by using screens and tilts. Once the investor’s portfolio has been adjusted, Nucleus Wealth provides the investor with a company profile, access to performance dashboards and detailed monthly performance reports of each company within the investor’s portfolio to further inform the investor on their investment decision and the company’s ethical standing as it aligns with the screens and tilts opted for. Nucleus Wealth utilises a number of domestic and international sources to identify whether companies from particular countries or sectors fall within the categories of screens and tilts which the investor may choose to apply. While Nucleus Wealth undertakes its own fundamental analysis on each company, there is also the risk that investors could reach a different conclusion to Nucleus Wealth on whether a company falls within the frame of responsible filters being applied. For more information visit ⁠⁠⁠⁠Nucleus Wealth's responsibility-related statements⁠⁠⁠⁠.